Labelling, projects and emblematic structures

• FHU TALISMENT

• Center of Excellence on Neurodegenerative diseases BIND

• GPR BRAIN 2030

• Labelled by IBISA and Bordeaux’s University of the Platform of Neuro-Psychopharmacologic Research

 Networks

Neurodegenerative diseases

• GDR 2905 “Neuroscience of Memory”

• French Multiple Sclerosis Observatory

• French Genetic analysis of multiple sclerosis Network

• Brief International Cognitive Assessment for MS

• CMRR Network

• NS-Park Network

• COEN Network (Networks of Centers Of Excellence in Neurodegeneration)

• European MSA Study Group, MDS-sponsored MSA Study Group

• MDS-sponsored PSP Study Group

Sleep, psychiatry and disability

• GDR 3737 “Sleep disorders and excessive diurnal somnolence”

• OpenLab STELLANTIS ‘Electronics and Systems for Automotive’

• Expert Centers on Resistant Depression (FondaMentale Foundation)

• Coordination of the Resistant Depression national network (FondaMentale Foundation)

• Scientific Cooperation Network on mental health  (FondaMentale Foundation)

• Industrial partnerships : AB Sciences, ABYSS INGREDIENTS, ACTELION, ACTIV’INSIDE, ALECTOR, ALEXION, ALNYLAM, ALZHEON, APELLIS, ARGENX BVBA, BAXALTA, BAYER HEALTHCARE, BIOGEN, BIOHAVEN, BIOPROJET, EISAI, HANSA BIOPHARMA, HOFFMAN, JANSSEN, JAZZ Pharmaceuticals, MERCK, MITSUBISHI PHARMA, NOVARTIS PHARMA, NOVONORDISK, PHARNEXT, ROCHE, SANOFI, SHANGAI GREEN VALLEY, TAU RX THERAPEUTICS, UCB
• Actions with associations, foundations, exhibition collaborations: Brain Week, Association France Parkinson, partnership with the Michael J. Fox Foundation, Sleep Day

• DIU (Inter-University Diploma) of the Pathology of inflammatory diseases of the central nervous system (Universities of Bordeaux, Toulouse, Limoges, Poitiers, Clermont, and Montpellier) (Prof. A.)

• DIU “Sleep and its pathology” (Prof. P. Philip, local university supervisor)

• Coordination of the Continuing Medical Education (Traffic Medicine, medical assessment of drivers’ capacity at the University of Bordeaux (Prof. P. Philip)

• DIU Multidisciplinary training in the management of Alzheimer’s disease and related syndromes

• University Diploma, Neurodegenerative Diseases — biological and clinical approaches: from pathophysiology to therapeutic strategies (UER Neurosciences)

2023

• Pouchieu C, Pourtau L, Brossaud J, Gaudout D, Corcuff JB, Capuron L, Castanon N, Philip P. Acute Effect of a Saffron Extract (Safr'InsideTM) and Its Main Volatile Compound on the Stress Response in Healthy Young Men: A Randomized, Double Blind, Placebo-Controlled, Crossover Study. Nutrients. 2023 Jun 27;15(13):2921. DOI:10.3390/nu15132921
• Philip P, Micoulaud-Franchi JA, Taillard J, Coelho J, Tisserand C, Dauvilliers Y, Sagaspe P. The Bordeaux Sleepiness Scale (BOSS): a new questionnaire to measure sleep-related driving risk. J Clin Sleep Med. 2023 May 1;19(5):957-965. DOI:10.5664/jcsm.10470
• Gavoille A, Rollot F, Casey R, Debouverie M, Le Page E, Ciron J, De Seze J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanche JP, Maurousset A, Moulin S, Ben NH, Boulos DD, Hankiewicz K, Neau JP, Pottier C, Nifle C, Rabilloud M, Subtil F, Vukusic S; Observatoire Français de la Sclérose en Plaques (OFSEP) Investigators. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference. Neurology. 2023 Mar 21;100(12):e1296-e1308. DOI:10.1212/WNL.0000000000206774

2022

• Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):608-619. DOI:10.1016/S1474-4422(22)00143-0
• Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Mult Scler Relat Disord. 2022 Jan;57:103385. DOI:10.1016/j.msard.2021.103385
• Wilson S, Calocer F, Rollot F, Fauvernier M, Remontet L, Tron L, Vukusic S, Le Page E, Debouverie M, Ciron J, Ruet A, De Sèze J, Zephir H, Moreau T, Lebrun-Frénay C, Laplaud DA, Clavelou P, Labauge P, Berger E, Pelletier J, Heinzlef O, Thouvenot E, Camdessanché JP, Leray E, Dejardin O, Defer G. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study. Lancet Reg Health Eur. 2022 Nov 17;24:100542. DOI:10.1016/j.lanepe.2022.100542

No current search for volunteers